title: [Analysis of antibodies of poliviruses in persistent populations in Beijing, 2012].
abstract: OBJECTIVE
  To analyze the polio immunity level of persistent population in Beijing, 2012.
  
  
  METHODS
  A total of 1 676 subjects residing more than 6 months in Beijing were selected by stratified random cluster sampling design in 2012. Demographic characteristics, history of oral poliovirus vaccine (OPV) immunization were investigated by questionnaire. All 5 ml blood sample were collected for testing of polio neutralizing antibody using the method of microcell neutralization. The positive rate and the geometric mean titer (GMT) of polio neutralizing antibody type I, II and III were analyzed in different groups.
  
  
  RESULTS
  The positive rate of type I, II and III were 98.2% (1 645/1 676), 98.1% (1 644/1 676), 97.6% (1 635/1 676); The GMT were 1:130.2, 1: 113.4 and 1: 79.7. Three types of positive rates in<15 years group (99.7% (664/666), 99.8% (665/666), 99.5% (663/666)) were higher than those of ≥ 15 years group (97.1% (981/1 010), 96.9% (979/1 010), 96.2% (972/1 010)), the differences were significant (all the values of P < 0.01); The GMT in<15 years group (1:325.9, 1:250.5, 1:190.7) were higher than that of ≥ 15 years group (1: 71.1, 1: 67.2, 1: 44.8), the difference was significant (all the values of P < 0.01). The positive rate (99.0%-100%) and GMT (1: 128.8-1: 300.7) in vaccination information confirmed population were higher. The highest positive rate (all were 100%) and GMT(1: 409.7-1: 636.7) were observed in children who vaccinated three times.
  
  
  CONCLUSIONS
  The polio antibody of healthy population was at a high level in Beijing in 2012; Especially the age groups of < 15 years which were covered by vaccines.Immunization barrier had been formed firmly to interrupt the transmission of wild poliovirus and vaccine-derived poliovirus.
authors.affiliation: Department of Immunization, Beijing Centers for Disease Control and Prevention, Beijing 100013, China.
authors.forename: Zhu Jiazi
authors.initials: ZJ
authors.lastname: Zhang
authors.forename: Herun
authors.initials: H
authors.lastname: Zhang
authors.forename: Renqing
authors.initials: R
authors.lastname: Li
authors.forename: Yang
authors.initials: Y
authors.lastname: Zeng
authors.forename: Xiaomei
authors.initials: X
authors.lastname: Li
authors.forename: Jingbin
authors.initials: J
authors.lastname: Pan
authors.forename: Hao
authors.initials: H
authors.lastname: Sun
authors.forename: Zhongzhan
authors.initials: Z
authors.lastname: Wang
authors.forename: Fangru
authors.initials: F
authors.lastname: Guo
authors.forename: Yihua
authors.initials: Y
authors.lastname: Zhang
authors.forename: Fengshuang
authors.initials: F
authors.lastname: Wang
authors.forename: Tao
authors.initials: T
authors.lastname: Wu
authors.forename: Xinghui
authors.initials: X
authors.lastname: Peng
authors.affiliation: Email: lulibj@sina.com.
authors.forename: Li
authors.initials: L
authors.lastname: Lu
authors.forename: Xinghuo
authors.initials: X
authors.lastname: Pang
mesh_terms: D056704:Adaptive Immunity; D000293:Adolescent; D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D002648:Child; D006801:Humans; D011051:Poliomyelitis; D017955:Poliovirus; D011055:Poliovirus Vaccine, Oral; D014611:Vaccination / Q000706:statistics & numerical data*
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D011055:Poliovirus Vaccine, Oral